StockData
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Avalyn Pharma Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$23.33−0.33 (-1.39%)

Close on Oct 19, 2026

Market cap
$691.75M
P/E (TTM)
–
Dividend yield
–

SEC filings

8 of Avalyn Pharma's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 15, 2026Sep 16, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 12, 2026SEC EDGAR
Current report8-KAug 12, 2026Aug 12, 2026SEC EDGAR
Current report8-KJun 29, 2026Jul 1, 2026SEC EDGAR
Current report8-KJun 17, 2026Jun 17, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026Jun 3, 2026SEC EDGAR
Current report8-KJun 3, 2026Jun 3, 2026SEC EDGAR
Current report8-KMay 1, 2026May 1, 2026SEC EDGAR